This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!
FDA Approves Hepatitis B Vaccine from Blood Source
The FDA authorized Heptavas-B, Merck's blood derived hepatitis B vaccine, marking the first such product in a decade. It targets high risk groups with a three shot, six month schedule priced about 75 to 120 dollars, and its protection duration remains under study.
MENTIONED IN THIS ARTICLE
FDA
Arthur Hull Hayes
Merck Sharp & Dohme
West Point
Maurice R. Hilleman
Merck
Associates
Lyons
Hilleman